| scholarly article | Q13442814 |
| P50 | author | Haval Shirwan | Q87621190 |
| P2093 | author name string | William S Bowen | |
| Lalit Batra | |||
| Hampartsoum Barsoumian | |||
| Abhishek K Svrivastava | |||
| P2860 | cites work | Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer | Q57152489 |
| Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation | Q81621807 | ||
| Cross-priming for antitumor CTL induced by soluble Ag + polyI:C depends on the TICAM-1 pathway in mouse CD11c(+)/CD8α(+) dendritic cells. | Q36194804 | ||
| The relationship between antigen concentration, antigen internalization, and antigenic complexes: modeling insights into antigen processing and presentation | Q36223215 | ||
| CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. | Q36284594 | ||
| Prime-boost vaccination with SA-4-1BBL costimulatory molecule and survivin eradicates lung carcinoma in CD8+ T and NK cell dependent manner | Q36384615 | ||
| SA-4-1BBL as a novel adjuvant for the development of therapeutic cancer vaccines | Q36487245 | ||
| CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases | Q36846646 | ||
| Mycobacterial heat shock proteins as vaccines - a model of facilitated antigen presentation | Q36855523 | ||
| Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer | Q36884975 | ||
| Vaccine immunopotentiators of the future | Q36959938 | ||
| Targeting CD4+CD25+FoxP3+ regulatory T-cells for the augmentation of cancer immunotherapy. | Q37024106 | ||
| Immunomodulation of TH2 biased immunity with mucosal administration of nanoemulsion adjuvant | Q37130834 | ||
| Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells | Q37139993 | ||
| Costimulation as a platform for the development of vaccines: a peptide-based vaccine containing a novel form of 4-1BB ligand eradicates established tumors | Q37370587 | ||
| Uncoupling T-cell expansion from effector differentiation in cell-based immunotherapy | Q37561102 | ||
| Tumor-mediated inhibition of dendritic cell differentiation is mediated by down regulation of protein kinase C beta II expression | Q37597961 | ||
| MHC class I antigen presentation and implications for developing a new generation of therapeutic vaccines | Q37709626 | ||
| Adjuvants for cancer vaccines | Q37757731 | ||
| Lympho-geographical concepts in vaccine delivery | Q37766372 | ||
| Bacterial ghosts as carriers of protein subunit and DNA-encoded antigens for vaccine applications | Q37965727 | ||
| Immune system targeting by biodegradable nanoparticles for cancer vaccines | Q38092551 | ||
| Receptor-mediated endocytosis and brain delivery of therapeutic biologics | Q38120524 | ||
| Type I IFN-mediated synergistic activation of mouse and human DC subsets by TLR agonists | Q38976179 | ||
| AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity | Q39782280 | ||
| The synergistic effects of combining TLR ligand based adjuvants on the cytokine response are dependent upon p38/JNK signalling. | Q40076470 | ||
| Synergistic activation of innate immunity by double-stranded RNA and CpG DNA promotes enhanced antitumor activity | Q40524997 | ||
| Co-stimulatory tumor necrosis factor ligands as adjuvants for the development of subunit-based anticancer vaccines | Q40724926 | ||
| Human tumor antigens recognized by T cells | Q41196996 | ||
| Tumour surveillance: missing peptides and MHC molecules | Q41745124 | ||
| The capacity of the TNF family members 4-1BBL, OX40L, CD70, GITRL, CD30L and LIGHT to costimulate human T cells | Q41947504 | ||
| SA-4-1BBL and monophosphoryl lipid A constitute an efficacious combination adjuvant for cancer vaccines | Q42186082 | ||
| Unique Th1/Th2 Phenotypes Induced during Priming and Memory Phases by Use of Interleukin-12 (IL-12) or IL-28B Vaccine Adjuvants in Rhesus Macaques | Q42411131 | ||
| Anti-CTLA-4 antibody treatment triggers determinant spreading and enhances murine myasthenia gravis | Q43600969 | ||
| Comparison of the immune responses to the CIA06-adjuvanted human papillomavirus L1 VLP vaccine with those against the licensed HPV vaccine Cervarix™ in mice | Q45240887 | ||
| CL097, a TLR7/8 ligand, inhibits TLR-4--dependent activation of IRAK-M and BCL-3 expression. | Q45766457 | ||
| ISCOMATRIX adjuvant induces efficient cross-presentation of tumor antigen by dendritic cells via rapid cytosolic antigen delivery and processing via tripeptidyl peptidase II. | Q46156041 | ||
| Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNγ response promoting vaccine immunogenicity | Q47110427 | ||
| Melanoma Sequentially Suppresses Different DC Subsets in the Sentinel Lymph Node, Affecting Disease Spread and Recurrence | Q47945837 | ||
| MF59 formulated with CpG ODN as a potent adjuvant of recombinant HSP65-MUC1 for inducing anti-MUC1+ tumor immunity in mice | Q49192661 | ||
| COX-2 inhibitor prevents tumor induced down regulation of classical DC lineage specific transcription factor Zbtb46 resulting in immunocompetent DC and decreased tumor burden. | Q51152940 | ||
| ISCOMATRIX() vaccines: Safety in human clinical studies. | Q51905178 | ||
| Synergism of Toll-like receptor-induced interleukin-12p70 secretion by monocyte-derived dendritic cells is mediated through p38 MAPK and lowers the threshold of T-helper cell type 1 responses. | Q51970784 | ||
| Peptide antigen priming of naive, but not memory, CD8 T cells requires a third signal that can be provided by IL-12. | Q52012684 | ||
| PD-1-Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer | Q56965739 | ||
| A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma | Q24319940 | ||
| Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer | Q24632187 | ||
| Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes | Q24680097 | ||
| Neoantigen-based cancer immunotherapy | Q26738693 | ||
| Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application | Q26858779 | ||
| Cancer vaccines | Q27024438 | ||
| TLR4 and TLR7/8 Adjuvant Combinations Generate Different Vaccine Antigen-Specific Immune Outcomes in Minipigs when Administered via the ID or IN Routes | Q27322386 | ||
| Nivolumab plus ipilimumab in advanced melanoma | Q27852310 | ||
| Crosstalk between Innate Lymphoid Cells and Other Immune Cells in the Tumor Microenvironment | Q28077126 | ||
| Approaching the asymptote? Evolution and revolution in immunology | Q28274344 | ||
| Versatile virus-like particle carrier for epitope based vaccines | Q28748358 | ||
| Regulated portals of entry into the cell | Q29547391 | ||
| ISCOMATRIX™ adjuvant promotes epitope spreading and antibody affinity maturation of influenza A H7N9 virus like particle vaccine that correlate with virus neutralization in humans. | Q30375901 | ||
| Mining the mutanome: developing highly personalized Immunotherapies based on mutational analysis of tumors | Q33606161 | ||
| 4-1BB ligand as an effective multifunctional immunomodulator and antigen delivery vehicle for the development of therapeutic cancer vaccines | Q33857971 | ||
| Inflammatory cytokines as a third signal for T cell activation | Q33936084 | ||
| ProtEx technology for the generation of novel therapeutic cancer vaccines | Q34048819 | ||
| Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells | Q34147162 | ||
| gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma | Q34188859 | ||
| Induction of T cell anergy: integration of environmental cues and infectious tolerance | Q34310174 | ||
| SA-4-1BBL costimulation inhibits conversion of conventional CD4+ T cells into CD4+ FoxP3+ T regulatory cells by production of IFN-γ | Q34369526 | ||
| Heat shock protein derivatives for delivery of antigens to antigen presenting cells | Q34709049 | ||
| Vaccine adjuvants aluminum and monophosphoryl lipid A provide distinct signals to generate protective cytotoxic memory CD8 T cells | Q34977848 | ||
| CD4+ T cells play a critical role in the generation of primary and memory antitumor immune responses elicited by SA-4-1BBL and TAA-based vaccines in mouse tumor models | Q34996924 | ||
| Novel human polysaccharide adjuvants with dual Th1 and Th2 potentiating activity | Q35003701 | ||
| Adjuvants and myeloid-derived suppressor cells: enemies or allies in therapeutic cancer vaccination | Q35886450 | ||
| ISCOMATRIX vaccines mediate CD8+ T-cell cross-priming by a MyD88-dependent signaling pathway | Q36001701 | ||
| Microenvironment abnormalities and lymphomagenesis: Immunological aspects. | Q36118020 | ||
| Immune response to cancer therapy: mounting an effective antitumor response and mechanisms of resistance | Q36125878 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 207-215 | |
| P577 | publication date | 2018-02-08 | |
| P1433 | published in | Expert Review of Vaccines | Q15756339 |
| P1476 | title | Current challenges for cancer vaccine adjuvant development | |
| P478 | volume | 17 |
| Q90398348 | Better Adjuvants for Better Vaccines: Progress in Adjuvant Delivery Systems, Modifications, and Adjuvant-Antigen Codelivery |
| Q95327672 | Harnessing nanomedicine to overcome the immunosuppressive tumor microenvironment |
| Q90397109 | Natural Compounds with Potential to Modulate Cancer Therapies and Self-Reactive Immune Cells |
| Q92071918 | Polyoxidonium® Activates Cytotoxic Lymphocyte Responses Through Dendritic Cell Maturation: Clinical Effects in Breast Cancer |
| Q92943708 | Self-Assembled, Adjuvant/Antigen-Based Nanovaccine Mediates Anti-Tumor Immune Response against Melanoma Tumor |
| Q64092940 | Therapeutic Cancer Vaccine and Combinations With Antiangiogenic Therapies and Immune Checkpoint Blockade |
Search more.